Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.
Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis.
Neuromuscular Determinants For Walking Performance In Individuals With Multiple Sclerosis: 2570 Board #93 June 3, 9: 30 AM - 11: 00 AM.
Hypofrontality and Posterior Hyperactivity in Early Schizophrenia: Imaging and Behavior in a Preclinical Model.
Clinical Profiles and Short-Term Outcomes of Acute Disseminated Encephalomyelitis in Adult Chinese Patients.
Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns.
IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity.
Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.
Fatigue in Multiple Sclerosis: Misconceptions and Future Research Directions.
ZFAT gene variant association with multiple sclerosis in the Arabian Gulf population: A genetic basis for gender-associated susceptibility.
Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse.
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.
Accelerated generation of oligodendrocyte progenitor cells from human induced pluripotent stem cells by forced expression of Sox10 and Olig2.
New 3-Times-Per-Week Regimen For Teva’s Copaxone Safe, Effective & Increases Patient Compliance #ECTRIMS2015
Combivent | Now
The Dress: Transforming a web viral event into a scientific survey.
Postreading Self-Assessment and CME Test-Preferred Responses.
Progressive Multiple Sclerosis.
Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.
Programmed cell death and natural killer cells in multiple sclerosis: new potential therapeutic targets?
An approach to comprehensive genome and proteome expression analyses in Schwann cells and neurons during peripheral nerve myelin formation.
Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.
Normal-appearing brain tissue analysis in radiologically isolated syndrome using 3 T MRI.
Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis.
No evidence for increased brain iron deposition in patients with ischemic white matter disease.

Pages